January 2006
Worldwide Biotech;Jan2006, Vol. 18 Issue 1, p5
Trade Publication
The article announces the launch of Glumetza, a formulation of metformin developed by Biovail Pharmaceuticals Canada which aimed to control diabetes mellitus in Canada. Biovail general manager Doug Herman offered a statement on metformin. Glumetza provides a significant advantage to both physicians and patients. Side effects of the drug are given. Diabetes is increasing in epidemic proportions each year in the country.


Related Articles

  • GSK revises Avandia labeling.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p19 

    The article reports on the plan of GlaxoSmithKline (GSK) to revise the U.S. product label of Avandia, the most widely used oral anti-diabetic medicine. This comes as a result of the review made by the Food and Drug Administration (FDA) of myocardial ischemic data on the drug. The revised drug...

  • SECTION 3: CENTRAL NERVOUS SYSTEM.  // Monthly Prescribing Reference;Apr2010, Vol. 26 Issue 4, p63 

    The article offers information on the medications and drugs used to treat central nervous system (CNS) diseases such as insomnia and anxiety. It states that Lunesta from Speracor is used for insomia but it can cause depression and behavioal changes. Meanwhile, CNS depression, dizziness, and...

  • News in brief...  // Reactions Weekly;6/19/2004, Issue 1006, p3 

    Presents news briefs on the pharmaceutical industry as of June 2004. Warnings issued by Biovail Pharmaceuticals on behavioral and emotional changes associated with the use of bupropion; Adverse reactions linked to parecoxib administration in Australia.

  • CENTRAL NERVOUS SYSTEM.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, p61 

    The article offers information on the labeling of several drugs for treatment of central nervous system diseases including Lunesta from Sepracor Pharmaceuticals, Restoril from Mallinckrodt Inc. and Ativan from Biovail Pharmaceuticals Inc. Lunesta is indicated for insomnia and is not recommended...

  • Warning About Byetta and Pancreatitis.  // Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32 

    The article reports that the U.S. Food and Drug Administration (FDA) has received complaints of acute pancreatitis among patients with type 2 diabetes who have been administered with Byetta. Out of the 30 patients, 27 had one or more risk factors for acute pancreatitis, such as gallstones or...

  • READERS SOUND OFF.  // Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32 

    The article presents the views of several readers of "Diabetes Health" on the issue that most diabetes drug trials focus on medication's effect on blood sugar levels, but ignore that medication's impact on other outcomes that are important to patients. One reader asserts that many of the...

  • Finally a warning.  // New Scientist;6/16/2007, Vol. 194 Issue 2608, p7 

    The article announces that the U.S. Food and Drug Administration (FDA) will add a more drastic warning label to the diabetes drug Avandia, created by GlaxoSmithKline. Drug makers who push for speedy approvals of new products often disregard the rushed studies of scientists and side effects are...

  • Insulin.  // Reactions Weekly;2/14/2004, Issue 988, p10 

    Presents the case of a 31-year-old pregnant woman who developed an allergy to insulin during treatment for gestational diabetes. Dosage of insulin taken by the patient; Symptoms developed at the insulin injection sites; Response of the woman to subcutaneous insulin lispro analogue and oral...

  • Avandia And Your Heart. D'Arrigo, Terri // Diabetes Forecast;Jul2007, Vol. 60 Issue 8, p16 

    The article deals with the report that type 2 diabetes drug Avandia (rosiglitazone) from GlaxoSmithKline can increase the risk of heart attack. A study published in the May 21, 2007 issue of "New England Journal of Medicine" revealed that diabetics who took Avandia had a greater chance of having...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics